BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 231 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q2 2020. The put-call ratio across all filers is 0.22 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $24,365,000 | +11670.5% | 161,174 | +11250.3% | 2.23% | +12300.0% |
Q2 2022 | $207,000 | -55.7% | 1,420 | -70.5% | 0.02% | -60.0% |
Q2 2021 | $467,000 | -49.2% | 4,808 | -61.8% | 0.04% | -57.5% |
Q2 2020 | $919,000 | +242.9% | 12,573 | +95.9% | 0.11% | +404.8% |
Q3 2019 | $268,000 | – | 6,419 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 2,111,111 | $144,294,000 | 54.16% |
Knoll Capital Management, LLC | 856,844 | $58,565,000 | 38.16% |
ORACLE INVESTMENT MANAGEMENT INC | 2,123,271 | $145,126,000 | 21.73% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 860,261 | $58,799,000 | 6.01% |
ARS Investment Partners, LLC | 561,442 | $38,375,000 | 4.46% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $12,057,000 | 3.19% |
Eventide Asset Management | 2,015,000 | $137,725,000 | 2.04% |
Avidity Partners Management LP | 1,049,800 | $71,754,000 | 1.98% |
SILVERARC CAPITAL MANAGEMENT, LLC | 50,089 | $3,424,000 | 1.87% |
Nicholas Investment Partners, LP | 375,654 | $25,676,000 | 1.79% |